Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 25:9:e13.
doi: 10.15420/cfr.2023.08. eCollection 2023.

Biomarkers to Improve Decision-making in Acute Heart Failure

Rafael de la Espriella  1 , Gonzalo Núñez-Marín  1 , Pau Codina  2 , Julio Núñez  1   3   4 , Antoni Bayés-Genís  2   4   5
Affiliations
Review

Biomarkers to Improve Decision-making in Acute Heart Failure

Rafael de la Espriella et al. Card Fail Rev. .

Abstract

Acute heart failure (AHF) is a complex clinical syndrome that requires prompt diagnosis, risk stratification and effective treatment strategies to reduce morbidity and mortality. Biomarkers are playing an increasingly important role in this process, offering valuable insights into the underlying pathophysiology and facilitating personalised patient management. This review summarises the significance of various biomarkers in the context of AHF, with a focus on their clinical applications to stratify risk and potential for guiding therapy choices.

Keywords: Acute heart failure; biomarkers; precision medicine.

PubMed Disclaimer

Conflict of interest statement

Disclosure: RdlE reports personal fees from AstraZeneca, Novartis, Boehringer Ingelheim and Novo Nordisk (outside the submitted work). GNM reports personal fees from AstraZeneca and Novo Nordisk (outside the submitted work). PC reports personal fees from AstraZeneca, Novartis, Boehringer Ingelheim and Abbott (outside the submitted work). JN reports personal fees from AstraZeneca, Novartis, Boehringer Ingelheim, Eli Lilly, Rovi, Novo Nordisk and Vifor Pharma (outside the submitted work). ABG reports personal fees and/or advisory board from AstraZeneca, Novartis, Boehringer Ingelheim, Abbott, Roche Diagnostics, and Vifor Pharma.

Figures

Figure 1:
Figure 1:. Diagnostic Work-up in Acute Heart Failure
Figure 2:
Figure 2:. Biomarkers for Identifying the Predominant Congestion Phenotype
Figure 3:
Figure 3:. Interpreting Haemoconcentration and Haemodilution During Decongestion
Figure 4:
Figure 4:. Biomarkers for Improving Recognition and Management of High-risk Patients
Figure 5:
Figure 5:. Multibiomarker Panel for Identifying the Predominant Heart Failure Phenotype
See this image and copyright information in PMC

References

    1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95. doi: 10.1067/mcp.2001.113989. - DOI - PubMed
    1. Ibrahim NE, Januzzi JL., Jr. Established and emerging roles of biomarkers in heart failure. Circ Res. 2018;123:614–29. doi: 10.1161/CIRCRESAHA.118.312706. - DOI - PubMed
    1. McDonagh TA, Metra M, Adamo M et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599–726. doi: 10.1093/eurheartj/ehab368. - DOI - PubMed
    1. Heidenreich PA, Bozkurt B, Aguilar D et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2022;145:e876–94. doi: 10.1161/CIR.0000000000001062. - DOI - PubMed
    1. de la Espriella R, Cobo M, Santas E et al. Assessment of filling pressures and fluid overload in heart failure: an updated perspective. Rev Esp Cardiol (Engl Ed) 2023;76:47–57. doi: 10.1016/j.rec.2022.07.009. - DOI - PubMed

LinkOut - more resources